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B RAF inhibitors are one of themost relevant findings inmelanoma therapy in the last 30 years, becoming first-line therapy for patientswithBRAFV600-mutantmeta-
staticmelanoma. Specifichigh-potency inhibitorsof theBRAF
proteinexhibithighoverall clinical response ratesofup to50%
compared with 5% with dacarbazine chemotherapy and can
achievemedianprogression-free survival of 6.3vs 2.9months,
with amedian overall survival in the dabrafenib group of 13.1
months.1,2
Although cutaneous adverse events occur in approxi-
mately 50% of patients, BRAF inhibitors have a manageable
toxicity profile.1-3 Numerous publications are reporting new
cutaneous adverse events of thesedrugs, but cutaneous squa-
mous cell carcinomas have definitely been the most signifi-
cant adverse effect in up to 35% of cases. Overall, approxi-
mately1 in3 treatedpatientsexperienceaseriousadverseevent
(grade III or IV), with most events being cutaneous.1,2
Newprimarymelanomashavebeen reportedduring anti-
BRAF treatment, especially in a vemurafenib series,which re-
ported new primary melanomas in approximately 2% of
patients.3-5 Dabrafenib appears to have an efficacy similar to
vemurafenib, but it is associatedwith less cutaneous toxicity
and photosensitivity and is generally well tolerated.1,2
Fewreportshavedrawnattention to thedifficult follow-up
andtreatmentofthesepatientsduringBRAFinhibitortreatment.
We describe 4 new primary melanomas in a patient in whom
early detectionwas possible bymeans of digital follow-up.
Report of a Case
A patient in her 30s who was 21 weeks pregnant was diag-
nosed as having high-riskmelanoma in her left submammar-
ian region (nodular ulcerated melanoma; Breslow index, 9.0
mm; Clark level, IV; and mitotic index, 6/mm2). She pre-
sentedwith a pathologic adenopathy on her axilla confirmed
by ultrasonography and fine-needle aspiration, but no other
evidence of distant metastasis was found on clinical labora-
tory testing (lactate dehydrogenase and S-100 protein levels
below the reference range), thoracic computed tomography,
and abdominal ultrasonography. She presented with mul-
tipleatypicalnevi,whichweremonitoredwith total-bodypho-
tographyanddigital dermoscopy.After surgical excisionof an
8-cm conglomerate mass in diameter and wide-margin exci-
sion of primary melanoma, she was diagnosed as having re-
sected stage IIIC disease.
IMPORTANCE BRAF inhibitors have become the standard of care in metastatic BRAF-mutant
melanomas. Compared with chemotherapies, BRAF inhibitors improve overall and
disease-free survival and speed the recovery of symptomatic patients with metastatic
disease. Themost worrisome finding is the possible development of resistance to new
malignant tumors.
OBSERVATIONS A patient in her 30s developedmassive BRAFV600E melanomametastasis
during her 30th week of pregnancy. After emergency cesarean delivery, oral dabrafenib
treatment was initiated, and a partial radiologic response was confirmed within 1 month. At
dermatologic digital follow-up aided by confocal microscopy 8 weeks after initiation of
dabrafenib treatment, 4 melanomas were detected. Unfortunately, within the next month,
themelanoma rapidly progressed. The 4 newmelanomas were wild-type BRAFmelanomas,
whereas the newmetastasis carried a different BRAFmutation (S467L).
CONCLUSIONS AND RELEVANCE Cutaneousmalignant tumors are themost frequent adverse
events of BRAF inhibitors; therefore, strict dermatologic surveillance in a referral center aided
by digital follow-up is mandatory, especially whenmultiple nevi are present and these drugs
are used in an adjuvant setting. In view of our findings, the pathogenesis of the development
of newmelanomas seems to be different from therapy resistance. Whether paradoxical RAF
activation could explain these BRAFwild-type secondary malignant tumors is still unknown.
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During the 30th week of pregnancy, she presented with
malaise, liver failure, and multiple melanoma metastases in
thebones, liver, andmesentery. Sheunderwentemergencyce-
sarean delivery and gave birth to a healthy, 1480-g, 31-week-
oldmale infantwhohadnoevidence ofmetastasis on thepla-
centa. Because BRAFV600E mutation was detected, oral
dabrafenib treatment was initiated at 150 mg twice daily. Af-
ter 7 days she recovered progressively, and a partial radio-
logic response was confirmed within 1 month.
At dermatologic digital follow-up 8weeks after initiation
ofdabrafenib treatment, 4 atypical lesionswith equivocal fea-
turesofmelanomaweredetected.Oneof them, locatedon the
lateral aspect of the neck, had massive regression features,
whereas the 3 other atypical melanocytic lesions, located on
the trunk, had increased global pigmentation and a dermo-
scopicnegativenetworkpattern (Figure 1andFigure2). Invivo
confocal microscopy was performed, and evident pagetoid
pleomorphic cells within epidermal layers (Figure 1C and
Figure 2D) were found in all 4 lesions. Simple surgical exci-
sion andhistopathologic study by 2 experienced pathologists
(A.G. and L.A.) were performed, and 4 superficial spreading
melanomas were diagnosed, in situ in melanoma specimen
sample 1 andClark level III associatedwith neviwith Breslow
indexes of 0.62, 0.41, and 0.64 mm in melanoma specimens
2, 3, and 4, respectively. Regression featureswere found in all
4 melanomas, but none of the tumors had ulceration or mi-
totic figures.
Unfortunately, within the next month, melanoma rap-
idly progressed, new lung andpleurametastasis developed in
a short period, and the patient died 5 months after initiation
of dabrafenib treatment.
All pathologic samples, including the 4 newly developed
melanomas, andpleuralmetastasiswere further studied to in-
vestigate molecular RAF and RAS status. Melanoma and ne-
vus cells were separately analyzed by means of laser capture
microdissection.Molecular characterization included the ge-
nomic analysesofBRAF (exon 11 and 15) andNRAS (exon2and
3) bypolymerase chain reactionanddirect sequencing, andall
investigated cell samples were wild type, except an unex-
pected different pathogenic BRAFmutation (S467L, exon 11)
detected only in pleural metastasis cells. In addition, germ-
line mutation analysis of melanoma susceptibility genes




A, Clinical image after 8 weeks of dabrafenib treatment. Arrowheads are
pointing to the suspicious pigmented lesions detected by digital follow-up.
B, Note that the 2 lesions labeled 2 and 3 were not clinically suspicious.
C, Dermoscopic image of lesion 2 showing a negative network pattern (whitish
lines with atypical irregular globules). D, Confocal examination revealed
pleomorphic nucleated atypical cells with pagetoid spreading within the
epidermis (500 × 500 μm). After excision, the lesions were diagnosed as
melanoma arising in compound nevi, with Breslow indexes of 0.4 and 0.35mm.
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(CDKN2A/CDK4/MITF) and family history of thediseasewere
assessed, and no increased risk of melanoma was identified.
Discussion
One of the most encouraging findings in the last decade re-
lated tooncologicdermatology is thedevelopmentofnew tar-
geted therapies formetastaticBRAF-mutantmelanomas. De-
spitewell-tolerated cutaneous toxic effects, all selectiveBRAF
inhibitor therapies are associatedwith thedevelopmentof be-
nign and malignant neoplasms, mainly squamous cell–
derived skin tumors andkeratoacanthoma-like squamous cell
carcinomas, but recently new primary melanomas have also
been reported.4 Case reports have included nonskin tumors
as well, such as RAS-mutant leukemia, the metastatic recur-
rence of RAS-mutant colorectal cancer, and gastric and co-
lonic polyps.6
The precise mechanism of this carcinogenesis is still un-
der investigation, but the induction of squamous cell carci-
nomas has been theoretically attributed to paradoxical acti-
vation of the mitogen-activated kinase (MAPK) pathway
managedby increasedactivityofRASandMAPKkinase (MEK)
downstream effectors when BRAF wild-type cells are ex-
posed to a selective BRAF inhibitor.6 However, regardingme-
lanocytic tumors,onestudy7 foundthatnevi that involutedur-
ing BRAF inhibitor therapy possess the BRAFV600E mutation,
whereas others that growor remainunchanged arewild type.
Few molecular studies are available regarding new mela-
nomas;however, the trendtoward increasedMEKeffectorsand
extracellular signal–regulated kinase signaling is suggestive of
a role for theparadoxicalMAPKactivationaswell.Todate,only
2newmelanomacaseshavebeenfoundtoharbortheNRASmu-
tation, but they are generally supposed to be BRAF andNRAS
wild type.4,8 Melanomas analyzed by laser microdissection in
the4caseswereallBRAF/NRASwild type.Theunexpecteddif-




A and B, Clinical images of the fourth melanoma tumor (arrowhead and number
4, respectively) after 8 weeks of dabrafenib treatment. C, Dermoscopic image
showing atypical pigmented network with focal hyperpigmentation and a
central negative network pattern similar to the other melanomas excised after
dabrafenib therapy. D, With confocal microscopy, roundish atypical nucleated
cells were detected within the whole epidermal layers and the subcorneal
stratum (500 × 500 μm). Similar findings of pagetoid spreading of pleomorphic
nucleated cells on the 4 lesions caused us to remove the 4 lesions.
E, Histopathologic analysis confirmed amelanomawith an associated nevus
and a Breslow index of 0.4mm (hematoxylin-eosin, original magnification ×10).
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ferentpathogenicBRAFmutation foundonly in thepleuralme-
tastasis cells, which was detected when resistance to therapy
evolved to lethal outcome, supports thehypothesisof adouble
metastatic population even though a newmutation cannot be
ruledout.However,noneof the4secondarymelanomas found
in this study (which were BRAFwild type) presented it.
Thenewregimensof concomitant therapywithBRAFand
MEK inhibitors could providehigher response rates andmore
durableclinicalbenefit thanmonotherapy,andtheyshouldab-
rogate the treatment-induced squamous cell carcinomas.9,10
However, in contrast to what was expected, the rate of mela-
nomas and other noncutaneous cancers that developed dur-
ing combined therapy seems to be the same as with BRAF
inhibitors.6 Our molecular findings could depend on differ-
ent pathogenicmechanisms to develop new secondarymela-
nomas (likely related to paradoxical activation of wild-type
cells) and to develop resistance to BRAF inhibitors (likely re-
lated to other pathogenic mutated cells), at least in our case.
Since Dalle et al11 reported the first 5 cases of new pri-
mary melanomas during vemurafenib therapy, more atten-
tion has focused on early diagnosis and the important role of
the dermatologist during follow-up. One limitation in the es-
timated incidence rates is the different protocol and training
of thephysician (ie, the rateof secondarymelanomascanrange
from 2% [by naked eye in published clinical trials] to 20% [by
digitalmonitoringas reportedbyPerier-Muzet et al5]). It iswell
known that digital follow-up by total-body photography and
digitalized dermoscopy is the most efficient strategy for the
earlydetectionofmelanomas inahigh-riskpopulation.12How-
ever,duringBRAFtherapies,more than50%of lesionscanhave
substantial changes during digital follow-up; therefore, addi-
tional data shouldbe taken intoaccount todeterminewhether
excision is necessary.4,5,13 Early melanomas detected by der-
moscopy were suspected because they presented relevant
changes in short-term follow-up that consisted of a negative
network pattern and changes in pigmentation. In vivo reflec-
tance confocal microscopy allowed us to improve our biopsy
rate index in doubtful lesions, as recently reported.14 The ob-
servationof large atypical dendritic and roundish cellswithin
epidermal layers was consistent in all cases. According to De-
barbieuxet al,15 these confocal features are suggestiveofmela-
noma after but not before BRAF inhibitor treatment.
Our 4 incipient caseswere diagnosed by the consensus of
2 experienced pathologists (A.G. and L.A.). The unresolved
questionabout themalignantpotentialof suchearlycasesmust
be taken into account. However, to date, the surgical excision
of anymelanocytic lesion that looks like amelanoma on der-
moscopy, confocal microscopy, and pathologic examination
is mandatory.
Conclusions
Perhaps themostworrisome toxic effect of BRAF inhibitors is
the emergence of secondary malignant neoplasms. Aware-
ness of all potential adverse effects of these agents is manda-
tory, especially if a role as an adjuvant therapy is approved af-
ter ongoing trials. Further investigations are needed to clarify
thepathogenicmechanismandwhetherMEK inhibitors could
abrogate the subjacent oncogenicmechanism. Because cuta-
neous squamous cell carcinomas and new primary melano-
masare themost frequentsevereadverseevents reported,strict
dermatologic surveillance in a referral center with well-
trained staff aided by digital follow-up is mandatory, espe-
ciallywhenmultiple nevi are presented and if these drugs are
used in an adjuvant setting in the future.
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Morphologicaldescriptionsofcutaneous lesions lendthemselvestocom-
parisonswith theworld aroundus, such as the realmsof food,1 animals,
orplants.2Over theages, thedermatology literaturehasalsobeendraped
with descriptive terms that conjure up ideas of style and fashion.
Mycosis fungoides is often described as having a bathing suit distri-
bution,asare the lesionsofangiokeratomacorporisdiffusuminFabrydis-
ease.Giantcongenitalmelanocyticneviwerecalledgarmentnevi, andhy-
pertrichosis lanuginose aquisita has been likened to a downy coat.
Coxsackie virusmaymanifest as papular-purpuric gloves and socks syn-
drome, and this distribution is also observed in the peripheral neuropa-
thyofpatientswithdiabetesmellitus. The shawl signandholster signare
well reported in dermatomyositis, and venous ulcers are typically found
over the gaiters’ area. Themittendeformity is observed in recessive dys-
trophicepidermolysisbullosa,andthedistributionof lesions inallergiccon-
tact dermatitis naturally draws on the culprit garb, such as belt buckle or
shoe dermatitis. Cylindromas are also known as turban tumors, chlo-
asma is sometimes called themaskofpregnancy, andpatientswith kera-
tosispilaris rougeappear tobewearingblusher.Morphologically, thebut-
tonholesign isclassicallyobservedinneurofibromasandanetoderma,and
the boutonnière deformity is seen in advanced rheumatoid arthritis.
The photosensitive nature of pellagra gives rise to a characteristic
gauntlet on the forearms as well as Cassal’s necklace over the décolle-
tage. Similarly, the hypomelanotic macules of secondary syphilis are
knownas thenecklaceofVenusand the termmonilethrix is derived from
the Latin term for necklace. The periungual papules of reticulohistiocy-
tosis have been liked to coral beads, and the annular bullae of linear IgA
bullous dermatosis are often described as a crown of jewels.
Tactile descriptions of cutaneous diseases also draw on compari-
sons with fabric. In tuberous sclerosis, the description shagreen patch
likens pathognomonic hamartomas to leather. Acanthosis nigricans is
said to feel like velvet, and woolly hair is observed in a number of
genodermatoses. The reticulate pattern of Wickham striae in lichen
planus is often described as lacy, as is the exanthem of erythema
infectiosum.
Beyond the realmof thenakedeye, trichoscopic examinationof pa-
tientswith looseanagensyndromedemonstratesacharacteristic “floppy
sock”appearance.Dermoscopically, numerous references to fashionare
reported, suchas theblue-grayveil seen inmelanomaor thehairpinves-
sels of keratinizing tumors.3 Pathologists arewell versed in the findings
of perivascular cuffing, the coat sleeve changes of erythema annulare
centrifugum, and the signet ring cells of adenocarcinomametastases.
The dermatological literature brimswith descriptions derived from
thesartorialworld.Given thevisualnatureofour specialty, it is littlewon-
der that such descriptions came into vogue.
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